On September 15, Amylyx Pharmaceuticals announced its intention to submit a New Drug Application to the FDA for AMX0035 for the treatment of ALS. If the New Drug Application is successful, AMX0035 would be only the third drug approved by …
Chicago Virtual NEALS ALS Clinical Research Learning Institute
The first-ever 2021 Chicago Virtual NEALS ALS Clinical Research Learning Institute (CRLI) was a great success! Thank you to all the patients, caregivers, and surviving family members who joined for the annual two-day program. Now, all attendees are certified as …
Research May Lead to New Ways to Combat ALS
Because we live in a changing environment, our survival and function depend on adapting to novel, potentially stressful, conditions. Is our ability to adapt to changing conditions fixed or is it possible to enhance our ability to tolerate a stressful …
Statement from Novartis Gene Therapies: OAV301 program for familial ALS caused by SOD1 mutation
Please see summary below from Novartis Gene Therapies on the OAV301 program for familial ALS caused by the SOD1 mutation: Novartis Gene Therapies (formerly AveXis) deeply appreciates the collaboration and support of the amyotrophic lateral sclerosis (ALS) community. Our ALS …
BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study
Today was a tough call for the ALS community, but not entirely disheartening. BrainStorm released the topline results this morning (November 17) from its Phase 3 trial for NurOwn® showing it did not meet statistical significance in its primary efficacy …
Amylyx Publishes CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS
We are excited to share some promising data regarding the CENTAUR trial evaluating AMX0035 in people with ALS on overall survival analysis, published today (October 16, 2020) in the neuromuscular disease journal Muscle & Nerve. The survival analysis followed each …
Data from Amylyx’s CENTAUR trial shows promise in slowing ALS progression
We are very pleased to share promising data published this week in the New England Journal of Medicine from the recent CENTAUR trial, conducted by Amylyx Pharmaceuticals, showing that AMX0035, the combination drug of sodium phenylbutyrate–taurursodiol, can slow functional decline …
Introducing the Joan & Paul Rubschlager Professorship
When Paul Rubschlager’s father was diagnosed with ALS in 1974, little was known about the cause of ALS and even less existed to help families facing this heartbreaking disease. After Paul’s father passed away in 1975, he and his wife …
Mechanisms Discovered Behind C9orf72 ALS Mutation
Evangelos Kiskinis, PhD, of our Les Turner ALS Center at Northwestern Medicine, alongside fellow Northwestern Medicine scientists, recently discovered the mechanisms and consequences behind ALS defect gene C9orf72. “A DNA mutation in a gene known as C9orf72 is responsible for …
New Study Evaluates Impact of Traumatic Brain Injury on ALS
The mission of our Les Turner ALS Center at Northwestern Medicine is to strive for a future without ALS by accelerating leading-edge research while providing life-enhancing treatment to people living with ALS. Our team at the Center, made up of …
